{"filing":{"accession_number":"0001437749-26-028916","cik":"0000072444","ticker":"VXRT","company_name":"Vaxart, Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-21","primary_document":"vxrt20260824_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774926028916/vxrt20260824_8k.htm"},"events":[{"id":29479,"run_id":26994,"accession_number":"0001437749-26-028916","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The Board formed two new committees (Clinical and Regulatory Affairs Committee and Stockholder Engagement Committee) and appointed specific directors to lead them. This is a governance restructuring that affects board oversight and stockholder relations. While not a traditional executive appointment or departure, the creation of new board committees with named leadership and the anticipated appointment of a new director pursuant to a Cooperation Agreement constitute material governance changes that would inform investors about the company's governance structure and strategic direction.","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31776,"accession_number":"0001437749-26-028916","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Board formed two new committees (Clinical and Regulatory Affairs Committee and Stockholder Engagement Committee) and appointed specific directors to lead them. This is a governance restructuring that affects board oversight and stockholder relations. While not a traditional executive appointment or departure, the creation of new board committees with named leadership and the anticipated appointment of a new director pursuant to a Cooperation Agreement constitute material governance changes that would inform investors about the company's governance structure and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:14:15.141808+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31776,"accession_number":"0001437749-26-028916","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Board formed two new committees (Clinical and Regulatory Affairs Committee and Stockholder Engagement Committee) and appointed specific directors to lead them. This is a governance restructuring that affects board oversight and stockholder relations. While not a traditional executive appointment or departure, the creation of new board committees with named leadership and the anticipated appointment of a new director pursuant to a Cooperation Agreement constitute material governance changes that would inform investors about the company's governance structure and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T20:14:15.141808+00:00","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-08-25"}]}